BioAge Labs, Inc. (BIOA)
| Market Cap | 798.72M +607.3% |
| Revenue (ttm) | 9.00M |
| Net Income | -80.61M |
| EPS | -2.24 |
| Shares Out | 44.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 229,898 |
| Open | 17.13 |
| Previous Close | 17.05 |
| Day's Range | 17.13 - 18.90 |
| 52-Week Range | 3.67 - 24.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 51.50 (+186.27%) |
| Earnings Date | May 7, 2026 |
About BIOA
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for BIOA stock is "Strong Buy." The 12-month stock price target is $51.5, which is an increase of 186.27% from the latest price.
News
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
BioAge Labs Inc (NASDAQ:BIOA) shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 inhibitor.
BioAge Labs Transcript: Study result
Phase I results for BGE-102 showed up to 86% CRP reduction and strong safety in obese subjects, with most patients reaching CRP below 2 mg/L. The drug demonstrated potent inhibition of IL-1β and IL-6, strong CNS/ocular penetration, and supports advancement into phase II cardiovascular and ophthalmology trials.
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose ...
BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing BGE-102, a novel NLRP3 inhibitor, into phase I and II trials for cardiovascular and ophthalmology indications, with promising early efficacy and safety data. Strong financials and sector interest support a robust pipeline, including APJ agonists for obesity.
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for ...
BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company presented strong phase I data for its oral NLRP3 inhibitor, showing best-in-class CRP reduction and favorable safety in obese patients. Key upcoming milestones include full phase I data, a three-month monotherapy trial, and a DME proof-of-concept study, with additional programs in obesity and ongoing pharma collaborations.
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates f...
BioAge Announces Proposed Public Offering
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates f...
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers
BioAge Labs Transcript: Piper Sandler 37th Annual Healthcare Conference
First clinical data for a brain-penetrant NLRP3 inhibitor showed strong target engagement and safety, with upcoming studies in obese patients focusing on CRP reduction. The pipeline includes differentiated assets and a robust cash position, with plans for both independent and partnered development.
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cy...
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m...
BioAge Labs Transcript: Jefferies London Healthcare Conference 2025
BioAge is advancing a unique NLRP3 inhibitor with strong brain penetration, focusing on cardiovascular and inflammatory benefits rather than weight loss, with phase I data expected by end of 2026. The APJ agonist program targets both oral and injectable obesity therapies, with IND filings planned for next year. Collaborations with Novartis and Lilly support early-stage discovery.
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m...
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to ac...
BioAge Labs Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Aging-focused platform integrates vast longitudinal human data and AI to identify novel metabolic and neurodegenerative targets. Lead NLRP3 inhibitor for obesity is in phase 1, with key data expected by year-end and a robust pipeline of APJ agonists advancing toward IND filings. Over $310M in cash supports multi-year development and strategic partnerships.
BioAge Labs Transcript: Citi's Biopharma Back to School Conference
The company leverages a proprietary platform to identify aging-related targets, advancing NLRP3 and APJ programs with strong preclinical and early clinical data. Key milestones include upcoming phase I and obesity trial readouts, with a robust cash position and strategic partnerships supporting pipeline growth.
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m...
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of propr...
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform ...
BioAge Labs Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
The company is advancing aging-focused metabolic disease programs, with a brain-penetrant NLRP3 inhibitor entering clinical trials and a next-generation apelin program in development. Strategic collaborations with Novartis and Lilly support novel target discovery, while a strong cash position enables progress toward key clinical milestones.
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases,...